Plain-English translation of NCT07605520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
The SOLVE-01 trial is comparing four different COVID booster vaccines: two experimental vaccines (CD40.RBDv and CD40.Pan.CoV, both combined with an immune-boosting ingredient called Hiltonol) and two already-approved boosters (Comirnaty and Nuvaxovid). The study will measure how safe these vaccines are and how well your immune system responds to them.
Researchers want to develop stronger and more protective COVID booster vaccines that can work against new variants. This medication is designed to trigger a more powerful immune response than current boosters, potentially offering better and longer-lasting protection.
You likely qualify if…
You likely don't qualify if…
You will receive one vaccine injection and two small skin tests. Over the next several weeks, you'll make 10 visits to the hospital for blood and saliva samples, physical exams, and routine health checks. You'll also keep a daily diary of any side effects or symptoms you experience and any medications you take. The entire study takes several months, and researchers will follow how your immune system responds to the vaccine over time.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France
Switzerland